Volume 34 Issue 6
Nov.  2018
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2018  >  34(6): 589-592
LU Zhen-qiang. Protective Effect of Hydroxysafflor Yellow A Combined with Astragaloside Ⅳ on Chronic Kidney Disease[J]. Journal of Nanjing University of traditional Chinese Medicine, 2018, 34(6): 589-592.
Citation: LU Zhen-qiang. Protective Effect of Hydroxysafflor Yellow A Combined with Astragaloside Ⅳ on Chronic Kidney Disease[J]. Journal of Nanjing University of traditional Chinese Medicine, 2018, 34(6): 589-592.
shu

Protective Effect of Hydroxysafflor Yellow A Combined with Astragaloside Ⅳ on Chronic Kidney Disease

  • Publish Date: 2018-11-10
    Abstract
  • OBJECTIVE To observe the preventive and therapeutic effects of hydroxysafflor yellow A combined with astragaloside Ⅳ on chronic kidney disease in rats and to explore its mechanism. METHODS 36 male Sprague-Dawley rats were randomly divided into sham operation group， model group and treatment group (HSYA+As-Ⅳ) by rat 5/6 nephrectomy model. One week after continuous administration， rats were sacrificed one month later. Serum levels of serum creatinine (Scr) and urea nitrogen (BUN) were measured before and after treatment in each group. The levels of SOD and MDA were measured to show oxidative stress changes. HE staining was used to observe the small groups. Histopathological changes in rat kidney， Western blot was used to detect SIRT1， eNOS and PGC-1α protein in kidney tissues of mice. RESULTS Compared with the model group， the treatment group reduced the levels of increased SCr and BUN， improved renal pathological changes， significantly reduced renal oxidative stress， and increased the expression of SIRT1， eNOS and PGC-1α proteins. CONCLUSION HSYA combined with As-Ⅳ may exert anti-chronic kidney disease through SIRT1/eNOS/PGC-1α pathway and oxidative stress.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    KHAN Z， PANDEY M. Role of kidney biomarkers of chronic kidney disease: An update[J]. Saudi J Biol Sci， 2014， 21(4): 294-299.
    [2]
    LEE SY， KIM SI， CHOI ME. Therapeutic targets for treating fibrotic kidney diseases[J]. Transl Res， 2015， 165(4): 512-530.
    [3]
    段昱方， 张海滨. 慢性肾脏病的中医治疗概况[J]. 现代中西医结合杂志， 2012， 21（28）: 3186-3189.
    [4]
    吴国伟， 吴劼扬， 郑卫华， 等. 慢性肾脏病与中医证型的关系探讨[J]. 浙江中医杂志， 2014， 49(8): 565-566.
    [5]
    董华玲， 马华. 中药芪红合剂对肾间质纤维化模型大鼠肾组织中基质金属蛋白酶组织抑制剂-1表达的影响[J]. 中国医药导报， 2008， 5(28): 5-8.
    [6]
    张选明， 杨百京， 叶学锋， 等. 补阳还五汤对肾间质纤维化大鼠模型胶原纤维和TGF-β1的作用[J]. 中药药理与临床， 2011， 27（6）: 3-6.
    [7]
    杨秀炜， 庞敏. 黄芪红花注射液合用对糖尿病肾病血流变的影响[J]. 辽宁中医杂志， 2003， 30(12): 994-994.
    [8]
    范愈燕， 吕翠岩， 朱斌， 等. 黄芪甲苷对链脲佐菌素诱导糖尿病大鼠肾脏保护机制探讨[J]. 中华中医药杂志， 2017， 32（1）: 294-298.
    [9]
    高燕， 谭虎， 常显， 等. 红花黄色素对糖尿病肾病的保护作用[J]. 中国老年学杂志， 2018， 38（6）: 1433-1435.
    [10]
    LITBARG NO， VUJICIC S， SETTY S， et al. A novel model of surgical injury in adult rat kidney: a "pouch model"[J]. Sci Rep， 2013（3）: 2890.
    [11]
    李忠， 张培华. 黄芪甲苷经TGF-β/Smad 信号通路对糖尿病肾病大鼠肾脏的影响[J]. 广东医学， 2016， 37(11): 1623-1628.
    [12]
    李会会， 胡娜平， 刘美佑， 等. 大黄酸和羟基红花黄色素 A 单用及配伍对慢性肾病的保护作用研究[J]. 药物评价研究， 2015， 38(6): 607-611.
    [13]
    张昶， 周鹰.黄芪在慢性肾病中的运用[J]. 新中医， 2009， 41（1）: 88-89.
    [14]
    毕立明， 朱冬云， 马济佩. 中西医对慢性肾脏病进展机制的共同认识及思考[J]. 辽宁中医杂志， 2011， 38(10): 2041-2043.
    [15]
    ZEISBERG M， NEILSON EG. Mechanisms of tubulointerstitial fibrosis[J]. J Am Soc Nephrol， 2010， 21(11): 1819-1834.
    [16]
    曹荣， 张晓燕， 康继宏. SIRT1在肾脏疾病中的作用[J]. 生理科学进展， 2013， 44(4): 305-309.
    [17]
    HE W， WANG Y， ZHANG MZ， et al. SIRT1 activation protects the mouse renal medulla from oxidative injury[J]. J Clin Invest， 2010， 120(4): 1056-1068.
    [18]
    KUME S， UZU T， HORIIKE K， et al. Calorie restriction enhances cell adaptation to hypoxia through SIRT1-dependent mitochondrial autophagy in mouse aged kidney[J]. J Clin Invest， 2010， 120(4): 1043-1055.
    [19]
    李博， 田瑞霞， 杨卫景. 等. PGC-1α的功能与代谢病[J]. 中国生物化学与分子生物学报， 2011， 27(11): 1013-1018.
    [20]
    TERESA CL， JOHN JL， BRIAN NF， et al. PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction， abnormal weight control and hepatic steatosis[J]. PLoS Biol， 2005， 3(4): 672-687.
    [21]
    FURRER R， HANDSCHIN C. Exercise and PGC-1α in inflammation and chronic disease[J]. Nature， 2015， 66(12): 317-320.
    [22]
    VALLE I， ALVAREZ-BARRIENTOS A， ARZA E， et al. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells[J]. Cardiovasc Res， 2005， 66(3): 562-573.
    [23]
    米琼宇， 邰婷， 潘玉琴， 等. 黄芪甲苷Ⅳ通过影响β-actin对内皮型一氧化氮合酶的调节作用[J]. 现代生物医学进展， 2013， 13(29): 5644-5648.
    [24]
    CHEN J， ZHOU Y， MUELLER-STEINER S， et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling[J]. J Biol Chem， 2005， 280(48): 40364-40374.
    [25]
    NISOLI E， TONELLO C， CARDILE A， et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS[J].Science， 2005， 310(5746): 314-317.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (659) PDF downloads(692) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return